about
Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relativesAlcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile.Mitochondrial haplogroups modify the risk of developing hypertrophic cardiomyopathy in a Danish population.The KCNE genes in hypertrophic cardiomyopathy: a candidate gene study.Private mitochondrial DNA variants in danish patients with hypertrophic cardiomyopathy.Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy.Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation RegistryLong-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry.Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy.Risk of Cardiomyopathy in Younger Persons With a Family History of Death from Cardiomyopathy: A Nationwide Family Study in a Cohort of 3.9 Million Persons.Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.MT-CYB mutations in hypertrophic cardiomyopathy.Long-term survival and causes of death in patients with ST-elevation acute coronary syndrome without obstructive coronary artery disease.Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial.Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy.Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.Left ventricular volume predicts exercise capacity in hypertrophic cardiomyopathy.Low procedure-related mortality achieved with alcohol septal ablation in European patients.Effect of impaired cardiac conduction after alcohol septal ablation on clinical outcomes: Insights from the Euro-ASA registryCardiomyopathy in Friedreich ataxia: exemplifying the challenges faced by cardiologists in the management of rare diseasesComparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathyNew and existing risk factors in patients with hypertrophic cardiomyopathyHypertrophic Cardiomyopathy in Childhood: Risk Management Through Family ScreeningPrimary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular CardiomyopathyShort- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysisAlcohol septal ablation in patients with severe septal hypertrophy
P50
Q28301903-854ADB7E-A548-40E8-B2B4-2CD694ADF4C0Q33162730-678CB4B5-D28A-478F-8E59-7ED5DC2A02BAQ34938120-C4EE7665-3C12-4E7E-96E8-CC0230DC3196Q35478355-8B09CF52-ECF1-4E1B-A83B-2DBB592180A5Q35552917-A25D63A9-7EE7-41F2-BDE0-C6EB548E0CFEQ38735647-C4C0D346-844B-4B2E-8A0F-D8743EBEB511Q39155585-FD0D272A-3987-43DB-B516-7DAF9E370E2AQ39178375-B731BAE5-2A0D-4CA4-9ED3-325B21B8A06FQ39747435-C0304503-2F46-4C27-B31A-ABFFD6025C39Q41479939-9273A028-87AA-41A1-9C1A-FA7A2B15FE75Q41657513-9570AFB6-BF35-49ED-BDE9-DE995CAD23B1Q46589649-172C0B89-42F2-4F8C-8186-D4C79EDDAA53Q47610705-8D51B3BF-A830-4497-9C8D-EDB81CA4C55CQ48090069-95B6C12D-F833-4B07-9ED4-A6C6CD1348D3Q49589965-7528F36E-95CE-4FD1-AF9A-CADE561B38E6Q50089449-4E887C4D-F54E-4D7F-BAEE-49519D7BCC6CQ50855630-7BAB2B13-1706-4C01-9E38-4963DB193C6DQ53170145-F7332541-875F-4CD1-A45F-39A8A2F1EA40Q57288558-532D34BA-9ED7-4070-9971-4622B1A9D504Q64040369-07A211AB-392E-4D5B-A761-D34C162C98ECQ84230810-260F4A73-4D58-4E46-A402-F2DCAAFD6F8CQ87207551-11756D94-116A-4EB8-8075-44C3CCB1FC3AQ88125461-03C556CA-34D7-4B24-AC8E-AF39D9C4F96EQ91207860-34889C56-1E4C-460C-BE36-921C03138949Q92454373-2AEC6356-6C11-4F82-B0B8-11D15EEA4BA0Q93022622-4B4A0CEF-7148-4DD7-86E8-90F28AB743F7
P50
description
investigador
@es
researcher
@en
name
Morten S Jensen
@en
type
label
Morten S Jensen
@en
prefLabel
Morten S Jensen
@en
P108
P31
P496
0000-0003-1144-4603